Abstract
Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.
| Original language | English |
|---|---|
| Pages (from-to) | 151-160 |
| Number of pages | 10 |
| Journal | International Archives of Allergy and Immunology |
| Volume | 121 |
| Issue number | 2 |
| State | Published - 2000 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Cite this
Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes. / Crocker, I. Caroline; Church, Martin K.; Ohia, S. Edet; Townley, Robert G.
In: International Archives of Allergy and Immunology, Vol. 121, No. 2, 2000, p. 151-160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes
AU - Crocker, I. Caroline
AU - Church, Martin K.
AU - Ohia, S. Edet
AU - Townley, Robert G.
PY - 2000
Y1 - 2000
N2 - Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.
AB - Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.
UR - http://www.scopus.com/inward/record.url?scp=0034051937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034051937&partnerID=8YFLogxK
M3 - Article
C2 - 10705226
AN - SCOPUS:0034051937
VL - 121
SP - 151
EP - 160
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
SN - 1018-2438
IS - 2
ER -